188532-26-5
基本信息
5-(3,5-二叔丁基-4-羟基苄基)噻唑烷-2,4-二酮
2,4-Thiazolidinedione, 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-
物理化学性质
| 沸点 | 446.5±40.0 °C(Predicted) |
| 密度 | 1.167±0.06 g/cm3(Predicted) |
| 储存条件 | Sealed in dry,Store in freezer, under -20°C |
| 溶解度 | DMSO: 250 mg/mL (745.25 mM) |
| 酸度系数(pKa) | 6.34±0.50(Predicted) |
| 形态 | Solid |
| 颜色 | White to off-white |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H312-H332 |
| 防范说明 | P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P330-P363-P501 |
常见问题列表
MitoNEET
NL-1 (10-100 μM; 72 hours; REH, REH/Ara-C and ALL cell lines) treatment reduces the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. NL-1 inhibits SUPB15, NALM6 with
IC
50
s of 29.48 µM, 94.26 µM, respectively. TOM1, BV173, NALM1 and JM1 all have similar
IC
50
values of around 60 µM for NL-1.
NL-1 (60 μM; 6 hours; REH, REH/Ara-C cell lines) treatment mediates autophagy, and inhibition of autophagy partially decreased NL-1-induced tumor cell death.
NL-1 pretreatment inhibits the chemotactic ability of both REH and REH/Ara-C cells to migrate towards multiple chemoattractants. The cells treated with NL1 shows a dose-dependent decrease in chemotaxis both in the REH and the REH/AraC cells.
Cell Proliferation Assay
| Cell Line: | REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines |
| Concentration: | 10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 100 μM |
| Incubation Time: | 72 hours |
| Result: | Reduced the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. |
Cell Autophagy Assay
| Cell Line: | REH, REH/Ara-C cell lines |
| Concentration: | 60 μM |
| Incubation Time: | 6 hours |
| Result: | Induced cell autophagy. |
NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model.
| Animal Model: | 10 female NOD.Cg- Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; daily; for 5 days |
| Result: | Showed antileukemic activity in an in vivo mouse ALL model. |